Skip to Content
Print Share

Generic OraVerse Availability

OraVerse is a brand name of phentolamine, approved by the FDA in the following formulation(s):

ORAVERSE (phentolamine mesylate - injectable;injection)

  • Manufacturer: SEPTODONT HOLDING
    Approval date: May 9, 2008
    Strength(s): 0.4MG/1.7ML [RLD]

Has a generic version of OraVerse been approved?

No. There is currently no therapeutically equivalent version of OraVerse available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OraVerse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Local anesthetic methods and kits
    Patent 6,764,678
    Issued: July 20, 2004
    Inventor(s): Eckard; Weber & Howard I.; Katz
    Assignee(s): Novalar Pharmaceuticals, Inc.
    Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
    Patent expiration dates:
    • May 11, 2021
      ✓ 
      Patent use: A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
  • Local anesthetic methods and kits
    Patent 6,872,390
    Issued: March 29, 2005
    Inventor(s): Weber; Eckard & Katz; Howard I.
    Assignee(s): Novalar Pharmaceuticals, Inc.
    Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
    Patent expiration dates:
    • May 11, 2021
      ✓ 
      Drug product
  • Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
    Patent 7,229,630
    Issued: June 12, 2007
    Inventor(s): Chen; Andrew X. & Knowles; Julius & Weber; Eckard
    Assignee(s): Novalar Pharmaceuticals, Inc.
    The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
    Patent expiration dates:
    • June 20, 2023
      ✓ 
      Drug product
  • Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
    Patent 7,569,230
    Issued: August 4, 2009
    Inventor(s): Chen; Andrew X & Knowles; Julius & Weber; Eckard
    Assignee(s): Novalar Pharmaceuticals, Inc.
    The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
    Patent expiration dates:
    • October 17, 2023
      ✓ 
      Patent use: A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
  • Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
    Patent 7,575,757
    Issued: August 18, 2009
    Inventor(s): Chen; Andrew X. & Knowles; Julius & Weber; Eckard
    Assignee(s): Novalar Pharmaceuticals, Inc.
    The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
    Patent expiration dates:
    • April 21, 2025
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 18, 2019 - NEW PATIENT POPULATION
Add to My Med List

More about OraVerse (phentolamine)

Consumer resources

Other brands: Regitine

Professional resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide